U.S. FDA Announces Joint Advisory Committee Review of Mallinckrodt's Abuse-Deterrent, Immediate-Release Reformulation of Roxicodone(R) (Oxycodone Hydrochloride)

Company Seeks Approval of New Drug Application for MNK-812 Through 505(b)2 Regulatory Pathway STAINES-UPON-THAMES, United Kingdom, Oct. 8, 2018 -- (Healthcare Sales & Marketing Network) -- Mallinckrodt plc (NYSE: MNK), a leading global specialty pharma... Biopharmaceuticals, Drug Delivery, FDA Mallinckrodt, Roxicodone, Oxycodone
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news